Cathie Wood's Biotech Bets: Risky but Potentially Lucrative Innovation Plays
• Cathie Wood's ARK Invest funds focus on disruptive innovation sectors like biotech and can provide stock ideas, despite high fees and volatility.
• Ginkgo Bioworks (DNA) provides biological engineering services and is expanding partnerships with major companies across industries. However, as a young public company it carries substantial risk.
• Recursion Pharmaceuticals (RXRX) uses AI and automation to accelerate drug discovery, especially in oncology. It has long-term upside potential but value is unproven.
• Analysts see upside for Recursion stock this year, though its novel platform must still demonstrate value over a 5+ year timeline.
• While risky, Ginkgo and Recursion represent speculative buys for aggressive investors, with substantial long-term growth possibilities.